Picture loading failed.

Anti-PDL1 therapeutic antibody (Pre-made Lodapolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lodapolimab is a fully human immunoglobulin G 1 lambda (IgG1λ) monoclonal antibody that binds to human PD-L1 expressed on tumour cells and tumor-infiltrating immune cells, prevents its binding to two receptors PD-1 and CD80 (B7-1), on the T cells.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-317-1mg 1mg 3090
GMP-Bios-ab-317-10mg 10mg 21890
GMP-Bios-ab-317-100mg 100mg 148000
GMP-Bios-ab-317-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-PDL1 therapeutic antibody (Pre-made Lodapolimab biosimilar,Whole mAb)
INN Name Lodapolimab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesDana-Farber Cancer Institute;Eli Lilly
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Development Techna